ProVerum, a MedTech startup based mostly in Dublin, has secured €68.6 million in Sequence B fairness financing to advance the commercialisation of its minimally invasive answer for benign prostatic hyperplasia (BPH).
The spherical was led by MVM Companions, with new backing from OrbiMed and the Eire Strategic Funding Fund (ISIF), and participation from current traders together with Lightstone Ventures, Enterprise Eire, Gilde Healthcare Companions, and Atlantic Bridge.
“I’m delighted to welcome MVM, OrbiMed and ISIF to the ProVerum crew,” mentioned Paul Bateman CEO of ProVerum Ltd. “That is an thrilling time for the corporate as we put together to commercialise our novel remedy for males with BPH.”
Based in 2016 by Dr Ríona Ní Ghriallais and Dr Conor Harkin, each alumni of the BioInnovate programme on the College of Galway, ProVerum emerged as a spin-out from Trinity School Dublin. The startup’s main focus has been the event of the ProVee System, an investigational gadget designed to supply a gentler various for treating BPH – a typical urological situation that impacts ageing males by enlarging the prostate and inflicting decrease urinary tract signs.
The ProVee System leverages a nitinol stent to reshape the enlarged prostate and relieve strain with out the necessity for invasive surgical procedure. It’s deployed via a versatile, steerable supply system with built-in imaging, matching the profile of office-based endoscopes sometimes utilized in urological diagnostics.
Whereas nonetheless restricted to investigative use in america and never but commercially accessible, the recent funding will help ProVerum’s push to carry ProVee to market.
Along with the funding, Hugo Harrod, Associate at MVM Companions, and Dina Chaya, Associate at OrbiMed, will be part of the startup’s board of administrators – marking a strategic enlargement of experience at a pivotal stage of economic readiness.
To this point, ProVerum has raised a complete of €106 million, together with a €25 million Sequence A spherical closed in early 2022.
MVM accomplice Hugo Harrod commented: “ProVerum exemplifies MVM’s give attention to disruptive medical merchandise addressing areas of true unmet want. We stay up for making use of our expertise in industrial stage medical expertise to help the Firm via its subsequent section.”
The announcement follows a notable milestone for certainly one of ProVerum’s long-standing backers. Caroline Gaynor, a Director at ProVerum and Associate at Lightstone Ventures, was lately appointed chairperson of the Irish Enterprise Capital Affiliation. She has management expertise throughout a number of high-growth firms, together with Amber Therapeutics, Carrick Therapeutics, Fire1 and Volta Medical.
OrbiMed Associate Dina Chaya added, “ProVerum has an modern minimally invasive remedy for BPH and is led by a first-class crew. We’re delighted to be supporting the Firm via the following stage of its development.“
